Skip to main content

Table 2 Demographic and baseline characteristics (ITT population)

From: Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial

Characteristic

Sapropterin + Phe- restricted diet (n = 27)

Phe-restricted diet only (n = 29)

Age, months

 mean±SD

21.1±12.3

21.2±12.0

 min; max

2; 47

2; 44

Age group, n (%)

 <12 months

7 (25.9)

8 (27.6)

 12 − <24 months

9 (33.3)

9 (31.0)

 24 − <48 months

11 (40.7)

12 (41.4)

 Males, n (%)

16 (59.3)

14 (48.3)

Height, cm

 mean±SD

82.0±11.3

82.3±11.6

 min; max

59; 108

57; 105

Weight, kg

 mean±SD

11.3±3.1

11.3±2.8

 min; max

5; 20

6; 16

BMI, kg/m2

 mean±SD

16.5±1.0

16.5±1.4

 min; max

14; 18

14; 20

Age at PKU diagnosis, days

 mean±SD

27.2±79.8

32.6±72.2

 min; max

1; 425

4; 382

Blood Phe concentration at diagnosis, μmol/L

 mean±SD

780.3±480.7

879.9 ± 596.5

 min; max

191; 2062

221; 2600

PKU severitya n (%)

 Classical PKU

5 (18.5)

7 (24.1)

 Mild PKU

10 (37.0)

8 (27.6)

 Mild HPA

12 (44.4)

14 (48.3)

  1. BMI body mass index, HPA hyperphenylalaninemia, ITT intention-to-treat, Phe phenylalanine, PKU phenylketonuria, SD standard deviation
  2. aDisease severity according to blood Phe concentrations: Classical PKU, >1200 μmol/L; Mild PKU, 600–1200 μmol/L; Mild HPA, 120–600 μmol/L2, 5, 6